	Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations. Ther Adv Med Oncol Giunta EF, De Falco V, Napolitano S, Argenziano G, Brancaccio G, Moscarella E, Ciardiello D, Ciardiello F, Troiani T. PMID: 32612709 [PubMed]
	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. Cancers (Basel) Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B. PMID: 32610581 [PubMed]
	Characterization of uveal melanoma clinical trial design: a systematic review to establish an elusive standard of care. Acta Oncol Zhang HG, Moser JC, Dalvin LA. PMID: 32609032 [PubMed - as supplied by publisher]
	Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: a population-based case-control study. Basic Clin Pharmacol Toxicol Daniels B, Pearson SA, Vajdic CM, Pottegård A, Buckley NA, Zoega H. PMID: 32608576 [PubMed - as supplied by publisher]
	KIT and Melanoma: Biological Insights and Clinical Implications. Yonsei Med J Pham DDM, Guhan S, Tsao H. PMID: 32608199 [PubMed - in process]
	Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. PMID: 32606047 [PubMed - in process]
	The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan. Trials Lo SN, Smit AK, Espinoza D, Cust AE, Managing Your Risk Study Group.. PMID: 32605576 [PubMed - in process]
	Targeted Therapy in Melanoma and Mechanisms of Resistance. Int J Mol Sci Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. PMID: 32605090 [PubMed - in process]
	MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. Int J Mol Sci Motti ML, Minopoli M, Di Carluccio G, Ascierto PA, Carriero MV. PMID: 32604720 [PubMed - in process]
	The Role of Neoadjuvant Therapy in Melanoma. Curr Oncol Rep Kelly ZR, Gorantla VC, Davar D. PMID: 32601947 [PubMed - in process]
	Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence? Acta Pharmacol Sin Zhao CX, Zeng CM, Wang K, He QJ, Yang B, Zhou FF, Zhu H. PMID: 32601365 [PubMed - as supplied by publisher]
	Reporting regression in primary cutaneous melanoma. Part 1: history, histological criteria and pathogenesis. Clin Exp Dermatol Cartron AM, Aldana PC, Khachemoune A. PMID: 32597504 [PubMed - as supplied by publisher]
	Triple Immunotherapy Overcomes Immune Evasion by Tumor in a Melanoma Mouse Model. Front Oncol Jallad MN, Jurjus AR, Rahal EA, Abdelnoor AM. PMID: 32596146 [PubMed]
	Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma. Ther Adv Med Oncol Nie RC, Yuan SQ, Wang Y, Zou XB, Chen S, Li SM, Duan JL, Zhou J, Chen GM, Luo TQ, Zhou ZW, Li YF. PMID: 32595775 [PubMed]
	Comment on "The Use of Non-Invasive Imaging Techniques in the Diagnosis of Melanoma: A Prospective Diagnostic Accuracy Study." J Am Acad Dermatol Sabour S. PMID: 32592883 [PubMed - as supplied by publisher]
	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol Immunother Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B. PMID: 32591862 [PubMed - as supplied by publisher]
	Survival of oral mucosal melanoma according to treatment, tumour resection margin, and metastases. Br J Oral Maxillofac Surg Chae YS, Lee JY, Lee JW, Park JY, Kim SM, Lee JH. PMID: 32586691 [PubMed - as supplied by publisher]
	Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. Clin Epigenetics Hoffmann F, Zarbl R, Niebel D, Sirokay J, Fröhlich A, Posch C, Holderried TAW, Brossart P, Saavedra G, Kuster P, Strieth S, Gielen GH, Ring SS, Dietrich J, Pietsch T, Flatz L, Kristiansen G, Landsberg J, Dietrich D. PMID: 32586358 [PubMed - in process]
	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. Cancers (Basel) Huynh S, Mortier L, Dutriaux C, Maubec E, Boileau M, Dereure O, Leccia MT, Arnault JP, Brunet-Possenti F, Aubin F, Dreno B, Beylot-Barry M, Lebbe C, Lefevre W, Delyon J. PMID: 32585901 [PubMed]
	Automatic diagnosis of melanoma using hyperspectral data and GoogLeNet. Skin Res Technol Hirano G, Nemoto M, Kimura Y, Kiyohara Y, Koga H, Yamazaki N, Christensen G, Ingvar C, Nielsen K, Nakamura A, Sota T, Nagaoka T. PMID: 32585082 [PubMed - as supplied by publisher]

Articles 1 - 20 / 106775

Page 1 of 5339



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy